M. Meissner

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

R. Butler, G. Schiavon, R. Venkitaraman, 2022, The Lancet. Oncology.

Intrathecal Methotrexate and Craniospinal Radiotherapy Can Be an Effective Treatment of Carcinomatous Meningitis in Patients with Breast Cancer: Case Reports

A. Addeo, M. Meissner, 2016, Case Reports in Oncology.

Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

Robin L. Jones, K. Thway, A. Napolitano, 2023, Expert opinion on pharmacotherapy.

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.

R. Butler, G. Schiavon, C. Twelves, 2022, Journal of Clinical Oncology.